A detailed history of Mercer Global Advisors Inc transactions in Bio N Tech Se stock. As of the latest transaction made, Mercer Global Advisors Inc holds 1,858 shares of BNTX stock, worth $210,195. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,858
Previous 3,283 43.41%
Holding current value
$210,195
Previous $263,000 16.35%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$78.36 - $124.66 $111,663 - $177,640
-1,425 Reduced 43.41%
1,858 $220,000
Q2 2024

Aug 12, 2024

SELL
$80.36 - $102.87 $504,017 - $645,200
-6,272 Reduced 65.64%
3,283 $263,000
Q1 2024

May 15, 2024

BUY
$88.96 - $112.35 $78,640 - $99,317
884 Added 10.19%
9,555 $881,000
Q4 2023

Feb 14, 2024

BUY
$90.91 - $112.75 $84,546 - $104,857
930 Added 12.01%
8,671 $915,000
Q3 2023

Nov 13, 2023

BUY
$98.5 - $125.08 $204,289 - $259,415
2,074 Added 36.6%
7,741 $841,000
Q2 2023

Aug 14, 2023

SELL
$102.58 - $129.66 $10,668 - $13,484
-104 Reduced 1.8%
5,667 $611,000
Q1 2023

May 15, 2023

SELL
$122.57 - $153.67 $62,878 - $78,832
-513 Reduced 8.16%
5,771 $718,000
Q4 2022

Feb 08, 2023

BUY
$118.43 - $186.05 $70,821 - $111,257
598 Added 10.52%
6,284 $944,000
Q3 2022

Nov 15, 2022

BUY
$127.65 - $183.11 $76,207 - $109,316
597 Added 11.73%
5,686 $767,000
Q2 2022

Aug 10, 2022

BUY
$123.25 - $186.24 $128,303 - $193,875
1,041 Added 25.72%
5,089 $759,000
Q1 2022

May 10, 2022

BUY
$126.25 - $231.85 $96,455 - $177,133
764 Added 23.26%
4,048 $690,000
Q4 2021

Feb 04, 2022

BUY
$216.64 - $362.52 $549,832 - $920,075
2,538 Added 340.21%
3,284 $847,000
Q3 2021

Nov 10, 2021

SELL
$205.93 - $447.23 $60,131 - $130,591
-292 Reduced 28.13%
746 $204,000
Q2 2021

Aug 10, 2021

BUY
$113.32 - $241.49 $117,626 - $250,666
1,038 New
1,038 $232,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.5B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Mercer Global Advisors Inc Portfolio

Follow Mercer Global Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.